Diatech Pharmacogenetics, the leading Italian Precision Medicine company. Diatech Pharmacogenetics is a provider of molecular diagnostic tools for precision medicine. The company aims at simplifying complex molecular diagnostic procedures into easy end-to-end solutions, from nucleic acids extraction and their molecular analysis, to final reporting. The company has 10 years of experience in the successful implementation of several nucleic acid analysis technologies into regulated diagnostic pipelines; examples include pyrosequencing, mass spectrometry and digital molecular barcoding. Leading cancer centres in Italy and abroad rely on Diatech CE-IVD solutions to extract nucleic acids from patient samples, analyse them with the most advanced technologies and interpret them with the latest bioinformatic algorithms. Excellence in each step of the diagnostic pipeline results in the personalisation of treatments, increased drug efficacy, reduced side-effects and ultimately better patient outcomes.
Link esterno per Diatech Pharmacogenetics
Via Ignazio Silone, 1b
Jesi, Ancona 60035, IT
ECM ONLINE GRATUITO: La medicina personalizzata nel trattamento del tumore alla prostata - UCBM Academy 📍 11 Luglio 2024 dalle ore 16.00 alle ore 19.00 📌 Clicca qui per iscriverti: https://lnkd.in/diZN3akv
Questo contenuto non è disponibile qui
Accedi a questo contenuto e molto altro nell’app LinkedIn
📌 We concluded the second meeting in presence of the Diatech Pharmacogenetics Scientific Board in the beautiful city of Bologna, a place rich in culture and art. It was a fruitful opportunity for exchange and enrichment, where each member generously shared their expertise. The contamination of diverse fields of study and the exceptionally high quality of each presentation provided us with numerous insights to guide our work and projects that will shape the future of our industry. 🌍 After an intense afternoon of work, the Professors were able to marvel at the unique and vast cultural heritage that the city offers. A special thanks to the chairman of the Scientific Board, Stefano Pileri, who guided us by revealing anecdotes and curiosities about his wonderful Bologna See you next year!
📢 Diatech Pharmacogenetics will attend the 36th European Congress of Pathology in Florence from September 7 to 11 🧬 You can find us at booth n. 115! European Society of Pathology #DiatechPharmacogenetics #Pathology
Questo contenuto non è disponibile qui
Accedi a questo contenuto e molto altro nell’app LinkedIn
Diatech Pharmacogenetics in qualità di sponsor dell'evento è lieta di invitarvi al "Training Course on Germline and Somatic Pharmacogenetics" il 12-13 settembre 2024 che si terrà a Cagliari. Responsabili Scientifici Monica Miozzo Matteo Floris
Questo contenuto non è disponibile qui
Accedi a questo contenuto e molto altro nell’app LinkedIn
🌞 Celebrating Our Summer Company Event! 🌞 We are thrilled to share the amazing moments from our recent summer company event, which brought together all our incredible employees for a day filled with fun, laughter, and team spirit. 🌟 A big thank you to everyone who participated and made this event unforgettable. Here's to many more moments of joy and collaboration! #CompanyEvent #TeamBuilding #SummerFun #CompanyCulture #EmployeeEngagement
👩🔬 Scientific research updates The EGFR mutational analysis was performed by real-time PCR on ctDNA of 118 lung cancer patients using Diatech EasyPGX Ready EGFR. This preliminary study shows that mutational analysis on ctDNA combined with serum tumor marker measurements may represent an integrated strategy for lung cancer monitoring. 👉 “Liquid biopsy and serum tumor markers in lung cancer: a real-life experience.” Arrigo C. et al., Clin Chem Lab Med 2023; 61, Special Suppl, pp S87 – S2222, May 2023. Poster Abstract P2055 – WorldLab • EuroMedLab Roma 2023 👉 Discover more about the EasyPGX ReadyEGFR Line: https://lnkd.in/etarFpCP
Precision oncology is transforming cancer care by tailoring therapies based on individual genetic profiles. Through this cutting-edge approach, we aim to improve outcomes and enhance the quality of life for patients worldwide. 🇧🇷 Join us in our mission to revolutionize cancer treatment! Connect with Mobius our Brazilian partner to learn more about how we are driving the future of precision medicine in oncology. Tommaso Carlini #PrecisionMedicine #Oncology #Pharmacogenetics #HealthcareInnovation #Mobius #DiatechPharmacogenetics #CancerCare
Juntos para Democratizar o acesso a testes com maior rapidez na #terapiapersonalizada A muito anos quando comecei um laboratório focado em testes de medicina personalizada, não tínhamos soluções como hoje podemos oferecer. Temos ferramentas práticas, acessíveis, aprovadas por organizações reguladores! Mobius Diatech Pharmacogenetics
🔎 Hey Colombia! Come and discover our EasyPgx System: https://lnkd.in/etarFpCP 👉 For information please contact our official distributor Gencell #EasyPGX #DiatechPharmacogenetics #Colombia
En Gencell te ofrecemos el portafolio más completo de medicina de precisión en oncología molecular🧬, a través de nuestra marca Diatech Pharmacogenetics y la plataforma EasyPGX con pruebas de PCR para diagnóstico personalizado en Cáncer. . . . . . #EasyPGX #Genética #farmacogenéticas #gencell #medicinagenomica #medicinadeprecision #oncología #cáncer #pruebasgenomicas #diagnósticomolecular #diagnósticopersonalizado #onocologiapediatri
🧬 Questa mattina gli studenti del secondo e terzo anno dell' Università Politecnica delle Marche sono venuti a visitare la nostra Azienda. Come sempre nelle ottime mani di Sara Cabodi e Alessandro Certelli hanno potuto vedere come ciò che studiano quotidianamente si mette in pratica all'interno di una realtà lavorativa. #keepgrowing #diatechpharmacogenetics #UnivPM
Diatech Pharmacogenetics ha diffuso questo post
📢 Mercoledì 19 Giugno 2024 ECM GRATUITO - online UCBM Academy "La biopsia liquida al servizio dell'oncologia". 📌 Dalle ore 16.00 alle ore 19.00 👩⚕️ È un dato oramai conclamato che l’oncologia di precisione, che prevede che specifiche alterazioni biologiche e genetiche del tumore diventino l’obiettivo di un trattamento individualizzato dando luogo a vere e proprie terapie “a misura di paziente”, è in grado di migliorare le percentuali di sopravvivenza nella fase metastatica della malattia, fino a raddoppiarle. Questo approccio nuovo, che prevede una vera e propria personalizzazione delle terapie (target therapy) necessita di una integrazione di competenze che provengono da diverse figure professionali coinvolte (oncologo, anatomopatologo, biologo molecolare, genetista e farmacologo) che, grazie alla loro esperienza, permettano una corretta interpretazione dei dati genetici e molecolari e la scelta della strategia terapeutica adeguata. 👉 Scarica il programma e iscriviti: https://lnkd.in/dPqp_dSb
Questo contenuto non è disponibile qui
Accedi a questo contenuto e molto altro nell’app LinkedIn